NCT05170971 Fecal Microbiota Transplantation for Liver Failure
| NCT ID | NCT05170971 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ningbo Medical Center Lihuili Hospital |
| Condition | Liver Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2021-05-01 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2021-05-01 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05170971 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Liver Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05170971 currently recruiting?
Yes, NCT05170971 is actively recruiting participants. Contact the research team at 13587646315@163.com for enrollment information.
Where is the NCT05170971 trial being conducted?
This trial is being conducted at Ningbo, China.
Who is sponsoring the NCT05170971 clinical trial?
NCT05170971 is sponsored by Ningbo Medical Center Lihuili Hospital. The trial plans to enroll 60 participants.